Showing results (361-370 of 781) with videos related to

Sort By:
Pageof 79
Immunological Reviews|December 17, 2014
Targeting the bone marrow microenvironment in multiple myelomaYawara Kawano, Michele Moschetta, Salomon Manier, et al.
Oncotarget|August 26, 2021
Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancerTeru Hideshima, Ralph Mazitschek, Jun Qi, et al.
The Journal of Biological Chemistry|February 11, 2005
Mitochondrial H2O2 regulates the angiogenic phenotype via PTEN oxidationKip M Connor, Sita Subbaram, Kevin J Regan, et al.
Communications Biology|May 25, 2021
Integrated genomics and comprehensive validation reveal drivers of genomic evolution in esophageal adenocarcinomaSubodh Kumar, Leutz Buon, Srikanth Talluri, et al.
Blood|May 14, 2010
Kidney disease associated with plasma cell dyscrasiasEliot C Heher, Nelson B Goes, Thomas R Spitzer, et al.
Hematology/Oncology Clinics of North America|November 13, 2007
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapiesConstantine S Mitsiades, Douglas W McMillin, Steffen Klippel, et al.
Molecular Cancer Therapeutics|December 21, 2002
Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironmentToshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, et al.
British Journal of Haematology|April 22, 2016
A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsArghya Ray, Durgadevi Ravillah, Deepika S Das, et al.
International Journal of Cancer|December 13, 2007
Risks of cancer among a cohort of 23,935 men and women with osteoporosisKatherine A McGlynn, Gloria Gridley, Lene Mellemkjaer, et al.
Biologics : Targets & Therapy|August 27, 2009
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasiasAldo M Roccaro, Irene M Ghobrial, Simona Blotta, et al.
Pageof 79